CA3123368A1 - Mitochondria-targeting peptides - Google Patents

Mitochondria-targeting peptides Download PDF

Info

Publication number
CA3123368A1
CA3123368A1 CA3123368A CA3123368A CA3123368A1 CA 3123368 A1 CA3123368 A1 CA 3123368A1 CA 3123368 A CA3123368 A CA 3123368A CA 3123368 A CA3123368 A CA 3123368A CA 3123368 A1 CA3123368 A1 CA 3123368A1
Authority
CA
Canada
Prior art keywords
compound
group
amino
ynh
h2nynh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3123368A
Other languages
English (en)
French (fr)
Inventor
Guozhu ZHENG
Mark J. BAMBERGER
Inese Smukste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of CA3123368A1 publication Critical patent/CA3123368A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3123368A 2018-12-18 2019-11-19 Mitochondria-targeting peptides Pending CA3123368A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862781153P 2018-12-18 2018-12-18
US62/781,153 2018-12-18
US201962892939P 2019-08-28 2019-08-28
US62/892,939 2019-08-28
PCT/US2019/062283 WO2020131282A1 (en) 2018-12-18 2019-11-19 Mitochondria-targeting peptides

Publications (1)

Publication Number Publication Date
CA3123368A1 true CA3123368A1 (en) 2020-06-25

Family

ID=71101606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3123368A Pending CA3123368A1 (en) 2018-12-18 2019-11-19 Mitochondria-targeting peptides

Country Status (9)

Country Link
US (2) US12404300B2 (enExample)
EP (1) EP3898652A4 (enExample)
JP (1) JP7614092B2 (enExample)
KR (1) KR20210093957A (enExample)
CN (1) CN113544138B (enExample)
AU (1) AU2019403856B2 (enExample)
CA (1) CA3123368A1 (enExample)
IL (2) IL284006B2 (enExample)
WO (1) WO2020131282A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
IL284006B2 (en) 2018-12-18 2024-12-01 Stealth Biotherapeutics Corp Mitochondria-targeting peptides
AU2019401254B2 (en) 2018-12-18 2025-05-01 Stealth Biotherapeutics Inc. Analogs that target mitochondrial diseases
CN118955233B (zh) * 2024-07-27 2025-05-06 康龙化成手性医药技术(宁波)有限公司 一种单取代双环[1.1.1]戊烷(bcp)的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
EP2547352A4 (en) 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
JP6319738B2 (ja) 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
WO2012022467A2 (en) 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
US8383919B2 (en) 2010-12-14 2013-02-26 Xueyun Gao Highly fluorescent peptide-metallic nanoclusters as bio-probes and methods of synthesis thereof
CN103764159A (zh) 2011-06-14 2014-04-30 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
EP3466439A1 (en) * 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
AU2013222237B2 (en) * 2012-02-23 2017-10-05 Cornell University Aromatic-cationic peptides and uses of same
WO2017093897A1 (en) 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017180535A1 (en) * 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
IL284006B2 (en) 2018-12-18 2024-12-01 Stealth Biotherapeutics Corp Mitochondria-targeting peptides
AU2019401254B2 (en) 2018-12-18 2025-05-01 Stealth Biotherapeutics Inc. Analogs that target mitochondrial diseases

Also Published As

Publication number Publication date
WO2020131282A1 (en) 2020-06-25
JP7614092B2 (ja) 2025-01-15
IL314309B1 (en) 2025-05-01
IL284006B1 (en) 2024-08-01
IL284006B2 (en) 2024-12-01
AU2019403856A1 (en) 2021-06-24
US20260055136A1 (en) 2026-02-26
IL314309A (en) 2024-09-01
US20220041653A1 (en) 2022-02-10
EP3898652A1 (en) 2021-10-27
JP2022511939A (ja) 2022-02-01
IL314309B2 (en) 2025-09-01
EP3898652A4 (en) 2022-08-24
IL284006A (en) 2021-08-31
KR20210093957A (ko) 2021-07-28
AU2019403856B2 (en) 2025-05-01
CN113544138A (zh) 2021-10-22
CN113544138B (zh) 2024-10-29
US12404300B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
JP7576670B2 (ja) ミトコンドリア標的化ペプチド
US20260055136A1 (en) Mitochondria-targeting peptides
AU2017249218B2 (en) Chiral peptides
JP7606966B2 (ja) ミトコンドリア病を標的とするアナログ
WO2019099481A1 (en) Deuterated tetrapeptides that target mitochondria
WO2021262710A1 (en) Prodrugs of mitochodria-targeting oligopeptides
CA3085772C (en) Mitochondria-targeting peptides
US20240059734A1 (en) Mitochondria-targeting peptides
HK40097183A (en) Mitochondria-targeting peptides
WO2021262708A1 (en) Prodrugs of mitochodria-targeting oligopeptides
HK40039982A (en) Mitochondria-targeting peptides
HK40035078A (en) Mitochondria-targeting peptides
HK40035078B (en) Mitochondria-targeting peptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240729

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20241010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250102

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250430

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250620

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251020

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215